STAR1,211.00

Strides Pharma Science Ltd.

· Pharma & Health
₹ CrorePeersSPARCSUPRIYASHILPAMEDTHYROCARERUBICONVIYASHYATHARTHPARKHOSPSMcap ₹11,162 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation220.7192.3202.4
+ Impairment Loss / (Reversal)0.01.1-2.8
+ Finance Costs314.4248.9178.5
+ Interest Income-30.40.00.0
+ Dividend Income0.0-48.0-40.5
+ Fair Value (Gains) / Losses0.0-102.10.0
+ Share-based Payments1.61.60.3
+ Unrealised FX (Gain) / Loss20.913.6-40.8
+ Other Non-cash Items157.8-9.3-107.3
+ Other — Cash Effects are Investing / Financing-5.7-2.1-1.3
Changes in Working Capital
+ Inventories30.7-217.0-284.5
+ Trade Receivables — Current39.1-51.6-109.3
+ Trade Payables — Current-148.5104.9310.7
+ Provisions — Current17.50.00.0
Cash from Operating Activities
Profit Before Tax (per I/S)58.8485.1668.2747.2
+ Total Adjustments (incl. Working Capital)618.0132.3105.4
Cash from Operations (pre-tax)676.8617.3773.6
+ Income Taxes Paid-24.2-67.071.1
Cash from Operating Activities701.1684.4702.5
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)118.2242.5422.9
+ Disp of Fixed Assets88.868.1119.3
+ Disp of Other Long-term Assets0.041.592.2
+ Purchase of Investments (Equity / Debt)15.10.00.0
+ Loans & Advances Made54.20.00.0
+ Dividends Received — Investing0.013.34.6
+ Interest Received — Investing15.30.00.0
+ Other Inflows / (Outflows) — Investing-66.929.833.9
Cash from Investing Activities-150.3-89.7-173.0
Cash from Financing Activities
+ Proceeds from Issue of Shares1.46.10.4
+ Proceeds from Other Equity Instruments51.30.00.0
+ Proceeds from Borrowings349.8171.4170.5
+ Repayment of Borrowings734.2763.7382.8
+ Payment of Lease Liabilities55.833.436.7
+ Interest Paid292.20.0167.9
+ Dividends Paid13.523.036.9
Cash from Financing Activities-693.3-642.6-453.4
Net Changes in Cash (pre-FX)-142.5-47.976.1
+ Effect of FX Rate Changes on Cash0.0-0.50.1
Net Changes in Cash-142.5-48.476.1
Closing Cash161.0112.6188.7
Reference Items
EBITDA743.3802.8925.3937.0
EBITDA Margin %18.3517.5819.0418.72
Free Cash Flow (CFO − Capex)582.9441.9279.6279.6
Free Cash Flow to Equity-177.0-15.3
Free Cash Flow per Basic Share63.2447.9430.3330.33
Price to Free Cash Flow39.92
Cash Flow to Net Income-7.430.191.22
Cash Paid for Taxes-24.2-67.071.1
Cash Paid for Interest292.20.0167.9
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.